Racotumomab

Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb) . Racotumomab reacts to Neu-glycolyl (NeuGc) -containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer[1][2][3].

Product Specifications

CAS Number

[946832-34-4]

Product Name Alternative

1E10

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/racotumomab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Racotumomab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Vázquez AM, et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2012 Oct 23;2:150. |[2]Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today (Barc) . 2014 Apr;50 (4) :301-7. |[3]Segatori VI, et al. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front Oncol. 2012 Nov 8;2:160. |[4]Truong CS, et al. Oncolytic Vaccinia Virus in Lung Cancer Vaccines. Vaccines (Basel) . 2022 Feb 4;10 (2) :240.